Eikon Therapeutics, Inc. Common Stock
EIKN
Get informed when a big investor buys or sells
+ FollowMarket Cap$25.82M
Close$
$-2.82
132.2% downside
Current Fair Value
132.2% downsideOvervalued by 132.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $25.82 Million |
|---|---|
| Enterprise Value | $119.10 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6.16 |
| Beta | 1.26 |
| Outstanding Shares | 54,138,555 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -2.91 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | 0.88 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | 2.14 |
| Debt to Equity | 0.46 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
$-1.98
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 10, 2026
EPS Estimate
$-1.61
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Eikon Therapeutics, Inc. Common Stock
484 employees
CEO: Roger Perlmutter Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops innovative medicines to address serious unmet medical needs. It develops a platform that permits precise characterization of pro...